First-line eradication of H pylori infection in Europe: A meta-analysis based on congress abstracts, 1997-2004

Table 1 Effect of PPI-based 1 wk triple therapies on the eradication of H pylori in European countries (pooled estimation of all treatment arms)

PPI+2AB	Cases (n)	Studies (n)	Treatment arms (n)	PER (%)	95% CI	P1	References
Omeprazole	7234	42	78	78.9	77.6-81.1		13-15, 17-19, 21-24, 26, 29, 37, 41, 43, 44, 49, 53, 57-63, 66-68, 73-76, 78-85
Lansoprazole	1048	12	17	82.9	79.2-81.1	0.95	12, 18, 22, 24, 25, 28, 32-38, 65
Pantoprazole	1216	9	13	80.1	76.5-83.6	0.84	27, 39-42, 63-65, 77
Rabeprazole	884	8	15	83.9	79.1-88.8	0.88	39, 49-56
Esomeprazole	752	6	14	81.1	80.3-88.0	0.80	43-48
All PPI	11134	77	136	81.4	78.5-84.5

¹ Omeprazole vs other PPIs; Test of homogeneity: Omeprazole, χ² = 6.12, P = 0.08; Lansoprazole, χ² = 5.56, P = 0.09; Pantoprazole, χ² = 1.46, P = 0.22; Rabeprazole, χ² = 3.45, P = 0.33; Esomeprazole, χ² = 1.96, P = 0.38.